Cellectar Biosciences, Inc. (CLRB)
CLRB moved a median of +0.27% 30 minutes after news, and 0.00% by the close. How CLRB actually reacts to news — the realized, point-in-time move the market made, measured across 265 labeled events over the last three years with zero look-ahead.
CLRB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 260 |
| 30-min | +0.27% | 52% | 264 |
| 60-min | 0.00% | 48% | 265 |
| to close | 0.00% | 49% | 262 |
| Middle 50% of CLRB reactions | -1.70% to +2.16% |
|---|---|
| Median reaction (30-min) | +0.27% |
| Measured reactions | 265 |
Half of all Cellectar Biosciences, Inc. news events land between -1.70% and +2.16% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CLRB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 28 | -1.50% | 25% | -2.75% |
| Rating reiterations | 10 | -0.23% | 40% | +0.37% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CLRB ranks against every other measured name →
That’s how CLRB usually reacts — get an email when it moves on news →Email me when CLRB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CLRB's baseline. Nothing else.
Recent CLRB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia | Press release | GlobeNewswire | +1.24% | -1.65% | |
| Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia | Press release | GlobeNewswire | -2.52% | -8.08% | |
| Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +2.99% | -1.20% | |
| Form 10-Q Cellectar Biosciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.99% | -1.20% | |
| Form 8-K Cellectar Biosciences, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +2.99% | -1.20% | |
| Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 | Press release | GlobeNewswire | — | +0.80% | |
| Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers | Press release | GlobeNewswire | +0.39% | +1.16% | |
| Form 8-K Cellectar Biosciences, For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | -6.41% | |
| Form EFFECT Cellectar Biosciences, | SEC filing · Form EFFECT | SEC EDGAR | -2.10% | -7.43% | |
| Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Press release | GlobeNewswire | -1.93% | -4.50% | |
| Form S-1/A Cellectar Biosciences, | SEC filing · Form S-1 | SEC EDGAR | -1.01% | +5.37% | |
| Form DEF 14A Cellectar Biosciences, For: Jul 07 | SEC filing · Form DEF | SEC EDGAR | -1.01% | +5.37% | |
| Form DEFA14A Cellectar Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | -1.01% | +5.37% | |
| Form S-1 Cellectar Biosciences, | SEC filing · Form S-1 | SEC EDGAR | -1.63% | +3.26% | |
| Form 8-K Cellectar Biosciences, For: May 17 | SEC filing · Form 8-K | SEC EDGAR | +4.91% | +0.00% | |
| Form PRE 14A Cellectar Biosciences, For: May 18 | SEC filing · Form PRE | SEC EDGAR | +4.91% | +0.00% | |
| Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +2.88% | +15.11% | |
| Form 10-Q Cellectar Biosciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.88% | +15.11% | |
| Form 8-K Cellectar Biosciences, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +2.88% | +15.11% | |
| Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 | Press release | GlobeNewswire | +4.10% | +4.44% | |
| Form 8-K Cellectar Biosciences, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -1.87% | -3.43% | |
| Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million | Press release | GlobeNewswire | -8.90% | -30.11% | |
| Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia | Press release | GlobeNewswire | -8.90% | -30.11% | |
| Form 10-K/A Cellectar Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.51% | +1.51% | |
| Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 | Press release | GlobeNewswire | +0.50% | -4.54% | |
| Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) | Press release | GlobeNewswire | +1.05% | +3.51% | |
| Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | Press release | GlobeNewswire | +5.74% | +3.94% | |
| Form 10-K Cellectar Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.74% | +3.94% | |
| Form 8-K Cellectar Biosciences, For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +5.74% | +3.94% | |
| Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 | Press release | GlobeNewswire | +0.29% | +0.29% | |
| Cellectar Biosciences Expands Global Intellectual Property Estate | Press release | GlobeNewswire | +0.00% | -6.59% | |
| Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference | Press release | GlobeNewswire | +1.80% | -7.78% | |
| Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | Press release | GlobeNewswire | +0.00% | -0.31% | |
| Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -7.76% | — | |
| Form 10-Q Cellectar Biosciences, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.76% | — | |
| Form 8-K Cellectar Biosciences, For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -7.76% | — | |
| Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 | Press release | GlobeNewswire | -2.10% | +3.00% | |
| Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma | Press release | GlobeNewswire | -1.65% | -7.71% | |
| Form S-1 Cellectar Biosciences, | SEC filing · Form S-1 | SEC EDGAR | +0.70% | -2.09% | |
| Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research | Press release | GlobeNewswire | -0.21% | +2.90% | |
| Form 8-K Cellectar Biosciences, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +2.67% | +4.49% | |
| Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million | Press release | GlobeNewswire | -2.96% | -3.75% | |
| Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) | Press release | GlobeNewswire | +5.00% | +2.83% | |
| Form 8-K Cellectar Biosciences, For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +5.00% | +2.83% | |
| Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer | Press release | GlobeNewswire | -1.66% | +3.51% | |
| Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) | Press release | GlobeNewswire | +2.02% | +11.15% | |
| Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 | Press release | GlobeNewswire | +1.61% | +9.54% | |
| Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit | Press release | GlobeNewswire | +0.00% | +4.75% | |
| Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September | Press release | GlobeNewswire | +1.40% | -0.60% | |
| Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research | Press release | GlobeNewswire | -1.04% | -0.62% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CLRB section they belong to.
Where else CLRB is measured.
CLRB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Qiagen N.V. Common Shares (QGEN) | 266 | +0.05% | 53% |
| 22nd Century Group, Inc (XXII) | 266 | -1.87% | 30% |
| EVOTEC AG S/ADR (EVTCY) | 265 | 0.00% | 17% |
| MiMedx Group, Inc (MDXG) | 265 | +0.14% | 57% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cellectar Biosciences, Inc.'s median reaction calculated?
Every labeled CLRB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 265 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of CLRB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CLRB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.